We are live on
!
Find out more
GCA
Greenwood Capital Associates Portfolio holdings
AUM
$1.02B
1-Year Est. Return
28.26%
This Fund
S&P 500
This Quarter
Est. Return
+4.49%
1 Year Est. Return
+28.26%
3 Year Est. Return
+81.29%
5 Year Est. Return
+95.78%
10 Year Est. Return
+421.94%
AUM
$397M
AUM Growth
+$8.31M
(+2.1%)
Cap. Flow
-$5.3M
Cap. Flow
% of AUM
-1.33%
Top 10 Holdings %
Top 10 Hldgs %
26.94%
Holding
208
New
42
Increased
62
Reduced
62
Closed
37
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$5.49M |
| 2 |
NVO
Novo Nordisk
NVO
|
+$4.25M |
| 3 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$4.17M |
| 4 |
iShares MSCI Global Gold Miners ETF
RING
|
+$4.15M |
| 5 |
Gilead Sciences
GILD
|
+$4.14M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$6.96M |
| 2 |
iShares Core MSCI Emerging Markets ETF
IEMG
|
+$6.06M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$5.8M |
| 4 |
Baker Hughes
BKR
|
+$5.25M |
| 5 |
iShares Core MSCI Total International Stock ETF
IXUS
|
+$4.68M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 12.49% |
| 2 | Communication Services | 10.26% |
| 3 | Technology | 9.58% |
| 4 | Consumer Discretionary | 8.95% |
| 5 | Industrials | 8.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
State Street Financial Select Sector SPDR ETF
XLF
$59.1B
| – | – |
-63,265
| Closed | -$1.63M |
|
202
State Street Industrial Select Sector SPDR ETF
XLI
$34.7B
| – | – |
-33,786
| Closed | -$2.54M |
|
203
State Street SPDR S&P Metals & Mining ETF
XME
$4.52B
| – | – |
-70,630
| Closed | -$2.1M |
|
|
MNDT
204
DELISTED
Mandiant, Inc. Common Stock
MNDT
| – | – |
-73,785
| Closed | -$1.24M |
|
|
MXIM
205
DELISTED
Maxim Integrated Products
MXIM
| – | – |
-5,211
| Closed | -$277K |
|
|
CXO
206
DELISTED
CONCHO RESOURCES INC.
CXO
| – | – |
-4,430
| Closed | -$492K |
|
|
STI
207
DELISTED
SunTrust Banks, Inc.
STI
| – | – |
-69,666
| Closed | -$4.13M |
|
|
CELG
208
DELISTED
Celgene Corp
CELG
| – | – |
-27,781
| Closed | -$2.62M |
|
Similar funds
SVCP
EFM
CC
MAM
GA
AG
MA
SB
Greenwood Capital Associates's Q2 2019 Portfolio in Review
As of Q2 2019, Greenwood Capital Associates held 208 positions worth $397M, up 2.1% from $389M the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Greenwood Capital Associates's Q2 2019 filing shows 42 new, 62 increased, 62 reduced and 37 closed positions. Its largest new stake was Merck: 71,722 shares worth $5.74M. The largest sale was Bristol-Myers Squibb, an estimated $6.96M.
By sector, the portfolio is most concentrated in Healthcare at 12% of assets, down from 13% a quarter earlier, followed by Communication Services and Technology.
- Greenwood Capital Associates's largest Q2 2019 buy was Merck: 71,722 shares worth $5.74M.
- Greenwood Capital Associates added most to Electronic Arts in Q2 2019, an estimated $3.23M increase.
- Greenwood Capital Associates's biggest Q2 2019 reduction was iShares Core MSCI Emerging Markets ETF, cutting an estimated $6.06M.
- Greenwood Capital Associates fully exited Bristol-Myers Squibb in Q2 2019, selling an estimated $6.96M.
- Greenwood Capital Associates's ten largest holdings make up 27% of its $397M portfolio in Q2 2019.
- Greenwood Capital Associates opened 42 new positions and closed 37 in Q2 2019.
- Greenwood Capital Associates's portfolio value rose 2.1% quarter-over-quarter to $397M.
Based on Greenwood Capital Associates's 13F filing for Q2 2019, filed 13 Aug 2019.